ALEFACEPT

6/4/02


Click here to start


Table of Contents

ALEFACEPT

Proposed Indication for Alefacept

Agenda

Biogen Consultants

Chronic Plaque Psoriasis

Patient Perspective: Moderate to Severe Psoriasis

Non-Cutaneous Burden of Disease

Current Therapies

Immunopathology of Psoriasis

Leukocyte Populations

Memory T Cells are Derived from Na´ve T Cells

Alefacept: A Fully Human Fusion Protein

Alefacept Mechanism of Action

Alefacept Targets Memory T Cells

Toxicology Program

Toxicology Program: Results

Clinical Program

Ongoing Clinical Development

Regulatory History

Author: Steven Ertel